Streetbeat News

Earnings

LUCD

Lucid Diagnostics (NASDAQ:LUCD) reported Q4 earnings with a per-share loss of $(0.23), surpassing the $(0.26) estimate. However, their sales of $1.04M fell slightly short of the $1.05M estimate. Despite the earnings beat, the loss per share has widened from $(0.15) a year ago, while sales have significantly increased from $112.00 thousand.

Portfolio Pulse from Happy Mohamed

March 25, 2024 | 9:44 pm

EQ

Equillium (NASDAQ:EQ) reported Q4 earnings with an EPS of $-0.07, beating estimates by 59.0% but with a revenue decrease of $6.55 million from the previous year. Despite beating EPS estimates, past performance shows a 5.0% drop in share price following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:35 pm

LUCD

PAVM

Lucid Diagnostics reported a 33% sequential increase in Q4 EsoGuard revenue, reaching $1.04M. The company's cash and equivalents stood at $18.9 million as of December 31, 2023, down from $22.5 million the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 9:33 pm

BNED

CATO

CZOO

GHG

In Monday's after-market session, several consumer discretionary stocks showed notable movements. Cato and GreenTree Hospitality Group reported their Q4 and FY earnings, respectively, leading to an increase in their stock prices. Other stocks such as SunCar Tech Gr, Noodles, and Purple Innovation also saw gains. Conversely, companies like Linkage Global, Cazoo Gr, and Barnes & Noble Education experienced declines in their stock prices.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:32 pm

AGRX

NBSE

OPGN

STOK

In Monday's after-market session, health care stocks saw significant movements. Stoke Therapeutics (STOK) led the gainers with a 77.7% increase following their Q4 earnings report, while Agile Therapeutics (AGRX) experienced the largest drop among the losers, declining by 54.7%. Other notable movers include OpGen (OPGN) with a 66.61% increase and NeuBase Therapeutics (NBSE) with a 54.53% decrease.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:32 pm

MPTI

M-Tron Industries (AMEX:MPTI) reported Q4 earnings with a significant miss on estimated earnings by -94.0%, posting an EPS of $0.03 against an estimate of $0.48. However, revenue increased by $2.10 million from the same period last year. In the previous quarter, the company exceeded EPS estimates which led to a 12.0% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:30 pm

AVTE

Aerovate Therapeutics (NASDAQ:AVTE) reported Q4 earnings with an EPS of $-0.74, missing estimates by -4.0%. Revenue remained unchanged from the previous year. Despite missing EPS estimates last quarter followed by a 15% share price increase, this quarter's performance may impact investor sentiment.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:20 pm

BKKT

Bakkt Holdings, Inc. (NYSE:BKKT) reported Q4 financial results with losses of 29 cents per share, missing analyst estimates. Sales were $15.1 million, slightly below expectations. Despite this, shares climbed due to strong FY24 revenue guidance ranging from $3.292 billion to $5.114 billion. The company plans to scale its business, expand its product set, and manage expenses efficiently. Bakkt's strengthened balance sheet and improving crypto market conditions contribute to a positive outlook for 2024.

Portfolio Pulse from Erica Kollmann

March 25, 2024 | 9:12 pm

WPRT

Westport Fuel Systems (NASDAQ:WPRT) reported Q4 earnings with losses of $(0.81) per share, missing the $(0.51) estimate by 58.82%, but saw a 19% improvement over last year's $(1.00) loss. Sales reached $87.20M, slightly above the $86.49M estimate, marking an 11.79% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 9:10 pm

HLGN

Heliogen (OTC:HLGN) reported Q4 earnings with an EPS of $-4.32, missing estimates by -16.0% and a revenue decrease of $5.88 million from the previous year. Despite beating EPS estimates last quarter, this marks a significant downturn.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 9:10 pm